Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Gold/Mining/Energy : Vasogen-- VAS on TSE -- Ignore unavailable to you. Want to Upgrade?

To: Julian who wrote (123)	4/10/1998 4:19:00 PM
From: g.b.88	Read Replies (1) \| Respond to of 377

Vasogen will report important news within this quarter (april-june). Including: * developments from Bristol on initial PAOD marketing reactions and such details, possibly including estimated revenue figures for '98 * Results from experimental Migraine study * Results from developmental Post-Operative Recovery study * Results from prospective Rheumatoid Arthritis study The most appealing aspect of the expected news is that if any of the results are positive, it will be a large boost to Vasogen's potential. On the other hand, these results would not essentially be viewed as backbreaking to Vasogen if results were negative. Note: Vasogen is presently trading at the bottom of the recent range. BOTTOM LINE: This is definitely the optimal time to buy Vasogen for long and short term investors. Regards, GB